Biotech Values

[DewDiligence]

>[Typo quiz] My guess is that it involves this statement : "Of the remaining $455M in regulatory milestones, half is for NDA/MAA submissions and half is for NDA/MAA approvals. Each half is divided among the U.S., EU, and Japan, but the exact geographic split has not been disclosed."
NDA/MAA submissions don't cover Japan.<

Actually, IDIX does get a regulatory milestone for the NDA (and the approval) in Japan, even though Japan is one of the NVS-only territories.

--
The typo is glaring and it’s in the slide—not in my annotations. (That’s why I couldn’t edit it out.)